Tianjin Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chesthospital.com
Clinical Trials
9
Active:0
Completed:1
Trial Phases
3 Phases
Phase 2:1
Phase 4:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (33.3%)Phase 2
1 (33.3%)Phase 4
1 (33.3%)TTE Improves Clinical Management of Stable Chest Pain
Recruiting
- Conditions
- Transthorcic EchocardiographyStable Angina PectorisCoronary Artery DiseaseMajor Adverse Cardiac EventsInvasive Coronary Angiography
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Tianjin Chest Hospital
- Target Recruit Count
- 50000
- Registration Number
- NCT07063147
- Locations
- 🇨🇳
Tianjin Chest Hospital, Tianjin, China
Optimal Evaluation to Reduce Cardiovascular Imaging Testing
Not Applicable
Recruiting
- Conditions
- Chronic Coronary Syndrome
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Tianjin Chest Hospital
- Target Recruit Count
- 800
- Registration Number
- NCT05640752
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Beijing, Beijing, China
🇨🇳Hebei Petrochina Central Hospital, Lanfang, Hebei, China
🇨🇳Tianjin First Central Hospital, Tianjin, Tianjin, China
Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Tianjin Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05578222
- Locations
- 🇨🇳
Tianjin Chest Hospital, Tianjin, China
CCTA Improves Clinical Management of Stable Chest Pain
Recruiting
- Conditions
- Stable Chest PainOptimal Medical TherapyRevascularizationInvasive Coronary AngiographyMajor Adverse Cardiovascular EventsCoronary Artery DiseaseCoronary Computed Tomography Angiography
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Tianjin Chest Hospital
- Target Recruit Count
- 50000
- Registration Number
- NCT04691037
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Beijing, Beijing, China
🇨🇳Hebei Petrochina Central Hospital, Langfang, Hebei, China
🇨🇳Tianjin Chest Hospital, Tianjin, Tianjin, China
Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
Phase 4
- Conditions
- Acute Coronary SyndromeProprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Tianjin Chest Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT04100434
- Locations
- 🇨🇳
Tianjin Chest Hospital,, Tianjin, China
- Prev
- 1
- 2
- Next
News
No news found